Episode Details
Back to Episodes
Biotech Surges as Natera Leads | Business and Finance News
Description
Biotech’s Q2 earnings delivered a strong surge, with 14 companies beating revenue forecasts by nearly 9%, keeping shares steady and up an average of 4.3%. Natera soared ahead with $752.8M in revenue—up 37.7% YoY and 13.6% above estimates—while also exceeding full-year guidance. In contrast, Myriad Genetics stumbled, posting a 10.5% YoY revenue drop and missing forecasts by 8.2%, marking the worst performance in the group. Regeneron also shined, reporting $4.29B in revenue (up 16.7%) and outperforming expectations by 12.4%, pushing its stock up 16.5%. Meanwhile, broader market concerns are shifting from AI’s impact on software pricing to new emerging risks, reshaping how biotech—and other sectors—are viewed by investors.
Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/0227efe87932f9cf